Siolta Therapeutics

Executive Summary

Siolta Therapeutics is a clinical-stage biotechnology company developing targeted live biotherapeutic products (LBPs) for diseases with high unmet medical need, leveraging its proprietary Precision Symbiotics Platform. Based in San Francisco, the company rationally designs synergistic bacterial combinations to modulate the human microbiome, focusing on conditions where microbiota play a central role. Siolta also develops molecular diagnostic tools and maintains in-house GMP manufacturing capabilities, enabling end-to-end control over product development. The company has advanced into Phase 2 clinical trials for its lead candidate, targeting a microbiome-driven disease with significant patient burden. Siolta's platform offers a differentiated approach by engineering consortia of bacteria that address core disease drivers, potentially improving efficacy and durability over single-strain or fecal transplant therapies. The company's vertical integration and focus on precise microbial therapeutics position it well in the growing microbiome market. Key upcoming value drivers include clinical data readouts from ongoing Phase 2 studies, which could validate the platform and attract partnership or financing interest. With a strategic focus on high-impact indications and robust manufacturing, Siolta is poised to capitalize on the increasing recognition of the microbiome's role in health and disease.

Upcoming Catalysts (preview)

• TBDPhase 2 data readout for lead LBP candidate60% success
• H2 2026Initiation of new Phase 2 trial in additional indication70% success
• 2026Regulatory advancement or IND filing for next-generation product65% success